摘要
目的:观察替吉奥联合奥沙利铂治疗进展期胃癌的疗效,探讨其对癌组织中基质金属蛋白酶-9(MMP-9)表达的影响。方法:120例进展期胃癌患者随机分为观察组和对照组,每组60例,均接受新辅助化疗方案治疗3个周期:观察组给予替吉奥胶囊联合奥沙利铂;对照组给予氟尿嘧啶联合奥沙利铂化疗。观察两组近期疗效、不良反应及化疗前后癌组织中MMP-9表达的变化。结果:治疗后,观察组和对照组客观缓解率差异无统计学意义(P>0.05),观察组临床受益率显著高于对照组(P<0.01);观察组重度骨髓抑制和肝肾功能损害发生率明显低于对照组(P<0.05);观察组MMP-9的阳性表达率明显低于对照组(P<0.05)。结论:替吉奥胶囊联合奥沙利铂可提高进展期胃癌患者的临床受益率,且能有效降低癌组织中MMP-9的表达。
Objective： To observe the efficacy of Tegafur gimeracil oteracil potassium （Gio） capsules combined with oxaliplatin in the treatment of advanced gastric cancer, and explore its effect on matrix metalloproteinase -9 （MMP-9） expression in cancer tissues. Methods： Totally 120 patients with advanced gastric cancer were randomly divided into the observation group and the control group, and both groups were treated with neoadjuvant chemotherapy for 3 cycles as follows： the observation group was given Gio capsules and oxaliplatin, and the control group was given 5-fluorouracil combined with oxaliplatin. The short term efficacy, adverse reactions and expression of MMP-9 in cancer tissue before and after the chemotherapy were observed in the two groups. Results： After the treatment, the objective response rate in the two groups had no significant difference （ P 〉 0.05 ） ; the clinical benefit rate of the observation group was significantly higher than that of the control group （ P 〈 0.05 ） ; the incidence of severe bone marrow suppression and liver and kidney dysfunction in the observation group was significantly lower than that in the control group （ P 〈 0.05 ） ; after the treatment, the positive expression of MMP-9 in the observation group was significantly lower than that in the control group （P 〈 0.05 ）. Conclusion： Gio capsules combined with oxaliplatin can improve the clinical benefit rate of the patients with advanced gastric cancer, and effectively reduce the expression of MMP-9 in cancer tissue.
出处
《中国药师》
CAS
2017年第11期2015-2017,共3页
China Pharmacist
基金
河北省唐山市科技局课题项目(编号:121302111b)
关键词
胃癌
替吉奥
新辅助化疗
基质金属蛋白酶-9
Gastric cancer
Tegafur gimeracil oteracil potassium capsules
Neoadjuvant chemotherapy
Matrix metalloproteinase-9
